AlloVir, Inc.

NasdaqCM ALVR

AlloVir, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 98.32%

AlloVir, Inc. Gross Profit Margin is 98.32% for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: ALVR

AlloVir, Inc.

CEO	Dr. Diana M. Brainard M.D.
IPO Date	July 30, 2020
Location	United States
Headquarters	1100 Winter Street
Employees	8
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Key trends

Past 5 years